June 26, 2020 / 12:13 AM / 17 days ago

BRIEF-FDA Approves New Therapy For Dravet Syndrome

June 25 (Reuters) - Zogenix Inc:

* FDA APPROVES NEW THERAPY FOR DRAVET SYNDROME

* U.S. FDA - APPROVED FINTEPLA, A SCHEDULE IV CONTROLLED SUBSTANCE, FOR TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME

* U.S. FDA - FDA GRANTED APPROVAL OF FINTEPLA TO ZOGENIX,

* U.S. FDA - FINTEPLA LABELING INCLUDES BOXED WARNING STATING DRUG IS ASSOCIATED WITH VALVULAR HEART DISEASE & PULMONARY ARTERIAL HYPERTENSION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below